PeptidePedia The community reference

User talk:SurvodutideSaff

Editor talk page·2 messages

This is the talk page for the editor SurvodutideSaff. Messages left here are public and are signed. Please add new messages at the bottom, and sign with four tildes.

Working group invitation

Given your edits around Timeline of incretin therapeutics, you might find the working-group pages useful — Project:Analytical working group, Project:Pharmacology working group and Project:Clinical evidence working group each keep a short priority list, and the priorities are mostly things one person can finish in an afternoon. — Chromatokid (talk) 07:30, 5 October 2025 (UTC)

Thank you. I have taken the one nobody had claimed, on the assumption that is where the shortage is. — SurvodutideSaff (talk) 06:16, 6 October 2025 (UTC)

Nomenclature in Semaglutide

Per Project:Manual of style the international non-proprietary name leads and the trade name follows in parentheses at first mention. Semaglutide has it the other way round in the lead and the right way round in the body. Not important in itself, but the articles are read side by side. — OrforglipronOona (talk) 14:49, 4 May 2026 (UTC)

Agreed. The trade name is how most readers arrive, which is presumably why I wrote it first, but the convention is the convention. — SurvodutideSaff (talk) 15:55, 5 May 2026 (UTC)